Suppr超能文献

口服牛奶过敏脱敏方案后不变自然杀伤细胞发生改变。

Invariant natural killer cells change after an oral allergy desensitization protocol for cow's milk.

机构信息

Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Clin Exp Allergy. 2017 Nov;47(11):1390-1397. doi: 10.1111/cea.12975. Epub 2017 Aug 23.

Abstract

BACKGROUND

Cow milk (CM) allergy (CMA) affects up to 3% of the paediatric population and recent data suggest that only about 50% will outgrow by age 8. Oral immunotherapy (OIT) is a type of immune-modulating treatment that is able to induce desensitization to food allergens, to increase tolerance threshold, to reduce the risk of anaphylaxis, and to improve the patient's quality of life. The examination of the immunological changes observed during the establishment of food allergy (FA) desensitization in FA patients is a window into the pathogenesis of food allergy and food tolerance development. In this pathway, we have previously found that invariant natural killer T cells (iNKTs) are involved in CM allergy sensitization and now examine their role in OIT.

METHODS

In this study, 10 of the 11 children with CM induced anaphylaxis enrolled in a CMA OIT clinical trial and completed the protocol. Peripheral blood iNKTs were quantitatively and qualitatively via flow cytometry characterized ex vivo and after culture with milk lipids before and after completing the OIT protocol.

RESULTS

After completing OIT for CM, children were able to reintroduce CM in their diet. For the first time, we demonstrated that OIT induced a significant increase in the peripheral blood iNKT, as well as their switch from a T helper (Th-2; ie IL-4, IL-13) to Th-1 (ie IFN-γ) cytokine profile.

CONCLUSIONS AND CLINICAL RELEVANCE

This study confirms the efficacy and safety of CM-OIT as well as the role of iNKT cells in CM allergy.

摘要

背景

牛奶过敏(CMA)影响多达 3%的儿科人群,最近的数据表明,只有约 50%的患者会在 8 岁时痊愈。口服免疫疗法(OIT)是一种免疫调节治疗,可以诱导食物过敏原脱敏,增加耐受阈值,降低过敏反应风险,并改善患者的生活质量。检查食物过敏(FA)脱敏过程中观察到的免疫变化是了解食物过敏和食物耐受发展发病机制的窗口。在这条途径中,我们之前发现不变自然杀伤 T 细胞(iNKT)参与了 CM 过敏致敏,现在研究它们在 OIT 中的作用。

方法

在这项研究中,11 名患有 CM 诱发过敏反应的儿童中有 10 名参加了 CMA OIT 临床试验并完成了方案。通过流式细胞术定量和定性地描述了外周血 iNKT,在进行 OIT 方案前后,用牛奶脂质进行体外和培养后进行描述。

结果

在完成 CM 的 OIT 后,儿童能够重新引入 CM 到他们的饮食中。我们首次证明,OIT 诱导外周血 iNKT 显著增加,以及它们从 Th-2(即 IL-4、IL-13)到 Th-1(即 IFN-γ)细胞因子谱的转变。

结论和临床相关性

这项研究证实了 CM-OIT 的有效性和安全性,以及 iNKT 细胞在 CM 过敏中的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验